{"id":"NCT04676412","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) [MK-7902-007/E7080-G000-314/LEAP-007] - China Extension Study","officialTitle":"A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) in Participants With Treatment-naïve, Metastatic Nonsmall Cell Lung Cancer (NSCLC) Whose Tumors Have a Tumor Proportion Score (TPS) Greater Than or Equal to 1% (LEAP-007)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-10-23","primaryCompletion":"2021-05-19","completion":"2024-03-29","firstPosted":"2020-12-21","resultsPosted":"2022-11-09","lastUpdate":"2025-04-04"},"enrollment":107,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Non-small Cell Lung Cancer"],"interventions":[{"type":"BIOLOGICAL","name":"Pembrolizumab","otherNames":["MK-3475","KEYTRUDA®"]},{"type":"DRUG","name":"Lenvatinib","otherNames":["MK-7902","E7080","LENVIMA®"]},{"type":"DRUG","name":"Placebo for lenvatinib","otherNames":[]}],"arms":[{"label":"Pembrolizumab + Lenvatinib","type":"EXPERIMENTAL"},{"label":"Pembrolizumab + Placebo","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to assess the safety and efficacy of pembrolizumab (MK-3475) combined with lenvatinib (MK-7902/E7080) compared to pembrolizumab alone (with placebo for lenvatinib) in treatment-naïve adults with no prior systemic therapy for their metastatic non-small cell lung cancer (NSCLC) whose tumors have a programmed cell death-ligand 1 (PD-L1) Tumor Proportion Score (TPS) greater than or equal to 1%.\n\nThe primary study hypotheses are that: 1) the combination of pembrolizumab and lenvatinib is superior to pembrolizumab alone as assessed by Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1); and 2) the combination of pembrolizumab and lenvatinib is superior to pembrolizumab alone as assessed by Overall Survival (OS).","primaryOutcome":{"measure":"Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)","timeFrame":"Up to approximately 18 months","effectByArm":[{"arm":"Pembrolizumab + Lenvatinib","deltaMin":6.1,"sd":null},{"arm":"Pembrolizumab + Placebo","deltaMin":10.3,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.71084"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":10,"exclusionCount":22},"locations":{"siteCount":17,"countries":["China"]},"refs":{"pmids":["38159809"],"seeAlso":["https://www.merckclinicaltrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":24,"n":49},"commonTop":["Proteinuria","Hypothyroidism","Aspartate aminotransferase increased","Anaemia","Diarrhoea"]}}